CCS
CLVS

Crosspoint Capital Strategies’s Clovis Oncology, Inc. CLVS Stock Holding History

Crosspoint Capital Strategies’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-62,215
Closed -$5.83M – 177
2017
Q2 		$5.83M Sell
62,215
-20,546
-25% -$1.26M 5.09% 1
2017
Q1 		$5.27M Sell
82,761
-1,315
-2% -$79.9K 4.42% 9
2016
Q4 		$3.73M Buy
+84,076
New +$2.96M 3.32% 10
2015
Q1 		– Sell
-50
Closed -$3K – 776
2014
Q4 		$3K Buy
+50
New +$2.63K ﹤0.01% 668

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Crosspoint Capital Strategies's CLVS Position: Q3 2017 in Review

Crosspoint Capital Strategies sold out of Clovis Oncology, Inc. (CLVS) in Q3 2017, closing a stake of 62,215 shares — an estimated $5.83M sold.

Crosspoint Capital Strategies first reported a position in CLVS in Q4 2014 and held it in 4 quarters. The position peaked at $5.83M in Q2 2017. 255 funds tracked by Wall St. Rank hold CLVS as of Q3 2017.

  • Crosspoint Capital Strategies reported no remaining Clovis Oncology, Inc. position as of Q3 2017 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 62,215 Clovis Oncology, Inc. shares in Q3 2017, an estimated $5.83M.
  • Crosspoint Capital Strategies first reported a position in Clovis Oncology, Inc. in Q4 2014 and held it in 4 quarters.
  • Crosspoint Capital Strategies's Clovis Oncology, Inc. position peaked at $5.83M in Q2 2017.
  • 255 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2017.

Based on Crosspoint Capital Strategies's 13F filing for Q3 2017, filed 6 Nov 2017.